208 related articles for article (PubMed ID: 7741239)
1. New concepts of iron and aluminium chelation therapy with oral L1 (deferiprone) and other chelators. A review.
Kontoghiorghes GJ
Analyst; 1995 Mar; 120(3):845-51. PubMed ID: 7741239
[TBL] [Abstract][Full Text] [Related]
2. Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1).
Kontoghiorghes GJ; Pattichi K; Hadjigavriel M; Kolnagou A
Transfus Sci; 2000 Dec; 23(3):211-23. PubMed ID: 11099897
[TBL] [Abstract][Full Text] [Related]
3. Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases.
Kontoghiorghes GJ
Indian J Pediatr; 1993; 60(4):485-507. PubMed ID: 8262586
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs.
Kontoghiorghes GJ
Toxicol Lett; 1995 Oct; 80(1-3):1-18. PubMed ID: 7482575
[TBL] [Abstract][Full Text] [Related]
5. Chemical, pharmacological, toxicological and therapeutic advances of deferiprone (L1) and other iron and aluminium chelators.
Kontoghiorghes GJ
Arch Toxicol Suppl; 1996; 18():202-14. PubMed ID: 8678796
[No Abstract] [Full Text] [Related]
6. Studies of aluminium mobilization in renal dialysis patients using the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
Kontoghiorghes GJ; Barr J; Baillod RA
Arzneimittelforschung; 1994 Apr; 44(4):522-6. PubMed ID: 8011008
[TBL] [Abstract][Full Text] [Related]
7. Chelation of aluminium by combining DFO and L1 in rats.
Blanusa M; Prester L; Varnai VM; Pavlović D; Kostial K; Jones MM; Singh PK
Toxicology; 2000 Jul; 147(3):151-6. PubMed ID: 10924797
[TBL] [Abstract][Full Text] [Related]
8. Iron chelation therapy.
Hoffbrand AV; Wonke B
J Intern Med Suppl; 1997; 740():37-41. PubMed ID: 9350180
[TBL] [Abstract][Full Text] [Related]
9. Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies.
Kontoghiorghes GJ; Bartlett AN; Hoffbrand AV; Goddard JG; Sheppard L; Barr J; Nortey P
Br J Haematol; 1990 Oct; 76(2):295-300. PubMed ID: 2094333
[TBL] [Abstract][Full Text] [Related]
10. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
Kontoghiorghes GJ; Aldouri MA; Hoffbrand AV; Barr J; Wonke B; Kourouclaris T; Sheppard L
Br Med J (Clin Res Ed); 1987 Dec; 295(6612):1509-12. PubMed ID: 3122880
[TBL] [Abstract][Full Text] [Related]
11. Results of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators.
al-Refaie FN; Hershko C; Hoffbrand AV; Kosaryan M; Olivieri NF; Tondury P; Wonke B
Br J Haematol; 1995 Sep; 91(1):224-9. PubMed ID: 7577638
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major.
al-Refaie FN; Wonke B; Hoffbrand AV; Wickens DG; Nortey P; Kontoghiorghes GJ
Blood; 1992 Aug; 80(3):593-9. PubMed ID: 1638018
[TBL] [Abstract][Full Text] [Related]
13. Zinc concentration in patients with iron overload receiving oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one or desferrioxamine.
al-Refaie FN; Wonke B; Wickens DG; Aydinok Y; Fielding A; Hoffbrand AV
J Clin Pathol; 1994 Jul; 47(7):657-60. PubMed ID: 8089225
[TBL] [Abstract][Full Text] [Related]
14. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients.
Hoffbrand AV; AL-Refaie F; Davis B; Siritanakatkul N; Jackson BF; Cochrane J; Prescott E; Wonke B
Blood; 1998 Jan; 91(1):295-300. PubMed ID: 9414297
[TBL] [Abstract][Full Text] [Related]
15. Iron chelation studies using desferrioxamine and the potential oral chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, in normal and iron loaded rats.
Kontoghiorghes GJ; Sheppard L; Hoffbrand AV; Charalambous J; Tikerpae J; Pippard MJ
J Clin Pathol; 1987 Apr; 40(4):404-8. PubMed ID: 3584483
[TBL] [Abstract][Full Text] [Related]
16. The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects.
Kontoghiorghes GJ; Pattichis K; Neocleous K; Kolnagou A
Curr Med Chem; 2004 Aug; 11(16):2161-83. PubMed ID: 15279556
[TBL] [Abstract][Full Text] [Related]
17. Urinary iron excretion depends on the mode of administration of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with homozygous beta-thalassemia.
Fassos FF; Klein J; Fernandes D; Matsui D; Olivieri NF; Koren G
Clin Pharmacol Ther; 1994 Jan; 55(1):70-5. PubMed ID: 8299320
[TBL] [Abstract][Full Text] [Related]
18. Oral iron chelation therapy with deferiprone. Monitoring of biochemical, drug and iron excretion changes.
Kontoghiorghes GJ; Bartlett AN; Sheppard L; Barr J; Nortey P
Arzneimittelforschung; 1995 Jan; 45(1):65-9. PubMed ID: 7893273
[TBL] [Abstract][Full Text] [Related]
19. Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease.
Collins AF; Fassos FF; Stobie S; Lewis N; Shaw D; Fry M; Templeton DM; McClelland RA; Koren G; Olivieri NF
Blood; 1994 Apr; 83(8):2329-33. PubMed ID: 8161801
[TBL] [Abstract][Full Text] [Related]
20. Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemia.
Mazza P; Amurri B; Lazzari G; Masi C; Palazzo G; Spartera MA; Giua R; Sebastio AM; Suma V; De Marco S; Semeraro F; Moscogiuri R
Haematologica; 1998 Jun; 83(6):496-501. PubMed ID: 9676021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
